New evidence reveals adult human hearts can regrow muscle cells after myocardial infarction, opening new possibilities for ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Transglutaminase 2 (TGM2) has been implicated in various health conditions, yet its role in acute coronary ...

In-hospital mortality was significantly lower in patients aged 90 years or older treated with PCI compared with medical management.

After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...

Analysis of the FOURIER trial shows that evolocumab provides greater MACE risk reduction in patients with higher BMI and stable ASCVD.

Sotagliflozin, a dual SGLT1/2 inhibitor, shows benefit specifically for reducing myocardial infarction and stroke risks. Among patients with type 2 diabetes and chronic kidney disease (CKD) at ...

India, Jan. 25 -- Concept Medical Inc, a global developer of drug-delivery technologies for cardiovascular interventions, has ...

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins. HealthDay News — For patients with myocardial infarction ...